Pinealon vs Vesugen
Well Studied vs Moderate Research
compatible Part of Khavinson bioregulator family; targets different tissue.
Molecular Data
Pinealon Vesugen
Weight 418.4 Da 390 Da
Half-life Not established Not established
Chain 3 amino acids 3 amino acids
Type Tripeptide Tripeptide bioregulator
Key Benefits
Pinealon
01 Direct DNA interaction
02 Neuroprotection
03 Cognitive enhancement
04 Excellent safety profile
05 40+ years of clinical use in Russia
Vesugen
01 Protects vascular system from aging effects
02 Limits atherosclerosis development
03 Decreases endothelial cell dysfunction
04 Activates SIRT1 anti-aging pathway
05 Enhances stem cell proliferation
06 Reduces cellular senescence markers
07 Reverses SASP phenotype
08 Works synergistically with Cardiogen
Dosing Protocols
Pinealon
Injectable: 5mg daily or 100-300mcg daily; Oral: 0.2mg twice daily / Injectable: daily for 20 days; Oral: morning and afternoon on empty stomach
Neuroprotection 5mg daily Once daily
Cognitive Enhancement 100-300mcg Daily or every other day
Anti-aging 5mg 20 days, 2-3x yearly
Vesugen
10-20 mg per day (oral capsules) or 10 mg (injectable) / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Research protocol 10 mg Daily for 10 days
Side Effects
Pinealon
Minimal injection site reactions
Mild gastrointestinal adjustment
Occasional headache
Fatigue
Vesugen
Generally well-tolerated
Minimal side effects reported
Contraindications
Pregnancy
Lactation
Active cardiovascular emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Research Evidence
Pinealon Vesugen
Status Well Studied Moderate Research
References 4 studies 3 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.